Cart is empty For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.
For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.
Leave A Comment